LIVIVO - Search results -

Search results

Result 1 - 10 of total 25

Search options

Article ; Online: The formation of complexes with albumin increases the stability of the protoporphyrin IX spectra.

Sulkowski, L / Matyja, A / Osuch, C / Matyja, M

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society

2023 Volume 74, Issue 4

Abstract: Photodynamic therapy is a high-target, low-invasive treatment utilized to manage a variety of malignant diseases and precancerous lesions. Protoporphyrin IX (PpIX) is one of the most important photosensitizers used in photodynamic therapy, carried to the ...

Abstract	Photodynamic therapy is a high-target, low-invasive treatment utilized to manage a variety of malignant diseases and precancerous lesions. Protoporphyrin IX (PpIX) is one of the most important photosensitizers used in photodynamic therapy, carried to the cancer tissue by serum albumin. Its delivery by transport protein is one of the major factors in determining the efficacy of photodynamic therapy. The distribution of the albumin-PpIX complexes to the target tissue enables the accomplishment of an optimal PDT effect. This study aimed to assess in vitro the stability of spectrofluorimetric spectra of albumin-PpIX complexes. The experiment used three chemicals: PpIX, human serum albumin (HSA), and bovine serum albumin (BSA). Spectral data was recorded using a Kontron SFM-25 Instrument AG, at two excitation wavelengths λ
MeSH term(s)	Humans ; Photosensitizing Agents/pharmacology ; Photosensitizing Agents/therapeutic use ; Serum Albumin/chemistry ; Protoporphyrins/chemistry ; Photochemotherapy/methods
Chemical Substances	protoporphyrin IX (C2K325S808) ; Photosensitizing Agents ; Serum Albumin ; Protoporphyrins
Language	English
Publishing date	2023-10-16
Publishing country	Poland
Document type	Journal Article
ZDB-ID	1125221-2
ISSN	1899-1505 ; 0867-5910 ; 0044-6033
ISSN (online)	1899-1505
ISSN	0867-5910 ; 0044-6033
DOI	10.26402/jpp.2023.4.10
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 1358: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Gender as a predictive factor in cholecystectomy - is it true or false?

Osuch, Czesław / Dolecki, Mirosław / Rogula, Wojciech Paweł / Łapiak, Aleksandra / Matyja, Maciej / Czerwińska, Agata / Rubinkiewicz, Mateusz / Matyja, Andrzej

Folia medica Cracoviensia

2020 Volume 60, Issue 2, Page(s) 97–107

Abstract: Introduction: Cholecystolithiasis is one of the most frequent disorders of the human digestive system in a present population. It is common to point out that male gender is one of strong risk factors for complications during cholecystectomy, however the ...

Abstract	Introduction: Cholecystolithiasis is one of the most frequent disorders of the human digestive system in a present population. It is common to point out that male gender is one of strong risk factors for complications during cholecystectomy, however the debate about that seems to be still open. Aim of the study: The aim of this study was to compare the values related to the course and treatment effects between gender in patients undergoing cholecystectomy, based on own material. Materials and methods: The study encompassed 504 patients who were admitted to General Surgery And Polytraumatic Injury Department of University Hospital in Kraków, Poland between 2013 and 2018, with the initial diagnosis of cholecystolithiasis (scheduled cases) and acute cholecystitis (emergency cases). The patients underwent surgical gallbladder removal. In this group there were 326 (64.7%) female and 178 (35.3%) male patients. Results: Statistically significant differences between both genders were found containing age, type of admission, numeric rating scale of pain during admission, results in American Society of Anesthesiologists physical status classification system, outcomes in Acute Physiology And Chronic Health Evaluation II severity-of-disease classification system, percentage of conversions, mortality, period of time from admission to surgical procedure, mean duration of the procedure, blood tests and histopathological results. Conclusions: Subgroups of the cases where determining factor is gender are strongly heterogeneous. Although treatment results were different for both subgroups and these differences were partly statistically significant, it cannot be clearly determined on the basis of a study with such selection of patients, that gender is an independent risk factor for surgical gallbladder removal.
MeSH term(s)	Adult ; Aged ; Cholecystectomy/adverse effects ; Cholecystitis, Acute/complications ; Cholecystitis, Acute/surgery ; Cholecystolithiasis/complications ; Cholecystolithiasis/surgery ; Female ; Humans ; Male ; Middle Aged ; Poland ; Postoperative Complications/etiology ; Prospective Studies ; Risk Factors ; Sex Factors ; Treatment Outcome
Language	English
Publishing date	2020-11-30
Publishing country	Poland
Document type	Comparative Study ; Journal Article
ZDB-ID	412415-7
ISSN	0015-5616
ISSN	0015-5616
DOI	10.24425/fmc.2020.135016
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 534: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Beneficial effect of kidney transplantation from a deceased donor on severe chronic refractory intradialytic hypotension - a case report.

Ignacak, Ewa / Cieniawski, Dominik / Bętkowska-Prokop, Alina / Osuch, Czesław / Kuźniewski, Marek / Sułowicz, Władysław

BMC nephrology

2017 Volume 18, Issue 1, Page(s) 248

Abstract: Background: Chronic refractory hypotension (IDH, intradialytic hypotension) is a rare but serious problem encountered in patients on hemodialysis. Patients with chronic hypotension are often disqualified by transplant teams from renal transplantation. ... ...

Abstract	Background: Chronic refractory hypotension (IDH, intradialytic hypotension) is a rare but serious problem encountered in patients on hemodialysis. Patients with chronic hypotension are often disqualified by transplant teams from renal transplantation. This is due to the possibility of an enormous risk of ischemic complications. Case presentation: We describe a 44-year old female patient with severe refractory hypotension (mean BP 60/30 mmHg, the lowest 48/28 mmHg), which appeared after bilateral laparoscopic nephrectomy of the infected kidneys. The kidney transplantation from a deceased donor, with infusion of the two pressor amines (dopamine, dobutamine) was performed without technical complications and the blood pressure measurements were 100-120/70-80 mmHg. The immunosuppression regimen was tacrolimus (TAC) + mycophenolate mophetil (MMF) and steroids (GS). Pressor amines were discontinued on the 18th day after the transplantation. Because of delayed graft function, 4 hemodialysis treatments were performed. The patient was discharged from the hospital on the 22nd day with good function of the transplanted kidney (the concentration of serum creatinine 117 μmol/l). During one-year follow-up, the patient has been remaining stable with a very good graft function (serum creatinine 84 μmol/l) and normal blood pressure (115/70 mmHg). Conclusions: Proper preparation and adequate perioperative treatment allowed for safely performing kidney transplantation in the patient with severe IDH.
Language	English
Publishing date	2017-07-20
Publishing country	England
Document type	Journal Article
ZDB-ID	2041348-8
ISSN	1471-2369 ; 1471-2369
ISSN (online)	1471-2369
ISSN	1471-2369
DOI	10.1186/s12882-017-0662-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST).

Rutkowski, Piotr / Bylina, Elżbieta / Lugowska, Iwona / Teterycz, Paweł / Klimczak, Anna / Streb, Joanna / Czarnecka, Anna M / Osuch, Czesław

Journal of geriatric oncology

2018 Volume 9, Issue 5, Page(s) 520–525

Abstract: Background: The aim of the study was to analyze the treatment results of advanced GIST in the largest, homogenous series of older patients.: Methods: Between 2001 and 2016, 686 patients with metastatic/unresectable GIST were treated initially with ... ...

Abstract	Background: The aim of the study was to analyze the treatment results of advanced GIST in the largest, homogenous series of older patients. Methods: Between 2001 and 2016, 686 patients with metastatic/unresectable GIST were treated initially with imatinib and 656 were included in the analysis. Subsequently 232 patients were treated with sunitinib after imatinib failure. We have analyzed the outcomes of patients who have been treated with the tyrosine kinase inhibitor at the age ≥ 70 years and compared to control group of patients younger than 70 years old. Results: In the group of patients treated with imatinib, 139 (21%) started therapy at the age of at least 70 years (median age of the entire cohort: 60). Median progression-free survival (PFS) on 1st line imatinib did not differ between patients ≥70 yo (years old) and < 70yo (38.5 vs 44.9 months), but median overall survival (OS) was significantly better for younger patients (81 months vs. 50; p = 0.0001; although disease-specific survival - DSS was similar). Distribution of primary tumor mutational status was generally similar in older and younger patients. Permanent dose reduction (300-100 mg/day) was required for 23 patients (16.9%) in the older group and was significantly more frequent as compared to younger patients (5%). Drug-related adverse events were mainly of grades 1/2, but grade 3/4 toxicity occurred more frequently in older (14.7%) than in younger patients (3.8%). Similarly in group of patients treated with second-line sunitinib median PFS and DSS were comparable in groups of patients ≥70 yo (n = 55) and < 70yo (9.7 months vs 10.3 months; p = 0.7, and 21.5 vs 22.9 months). >40% of patients in both groups required dose adjustments to 37.5-25 mg daily. Conclusions: Our study confirms that current therapy of advanced GIST with tyrosine kinase inhibitors (both in 1st and 2nd line) in older patients enable to achieve the similar disease control rate and final outcomes as in younger patients, but it demands close cooperation of experienced oncologist with patients for dose modifications and side effects management. Limitation of our study is that the patients did not undergo a comprehensive geriatric assessment, what might be helpful for personalized management of patients. Nevertheless, we confirm that older patients with GIST should not receive less treatment irrespective of comorbidities.
MeSH term(s)	Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Female ; Gastrointestinal Neoplasms/drug therapy ; Gastrointestinal Stromal Tumors/drug therapy ; Humans ; Imatinib Mesylate/administration & dosage ; Imatinib Mesylate/adverse effects ; Male ; Middle Aged ; Progression-Free Survival ; Prospective Studies ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Sunitinib/administration & dosage ; Sunitinib/adverse effects ; Young Adult
Chemical Substances	Protein Kinase Inhibitors ; Imatinib Mesylate (8A1O1M485B) ; Sunitinib (V99T50803M)
Language	English
Publishing date	2018-03-27
Publishing country	Netherlands
Document type	Journal Article ; Observational Study
ZDB-ID	2556813-9
ISSN	1879-4076 ; 1879-4068
ISSN (online)	1879-4076
ISSN	1879-4068
DOI	10.1016/j.jgo.2018.03.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Influence of Cytochrome P450, ABC and SLC Gene Polymorphisms on Imatinib Therapy Outcome of Patients with Gastrointestinal Stromal Tumours (GIST).

Wasielewski, K / Wasag, B / Wozniak, A / Pikiel, J / Kowalik, A / Osuch, C / Bylina, E / Siedlecki, J A / Rutkowski, P / Limon, J

Folia biologica

2016 Volume 63, Issue 2, Page(s) 78–83

Abstract: The efficacy of imatinib-based therapy depends on the proteins involved in its metabolism and transportation. Therefore, the aim of our study was to investigate the possible correlation of selected P450, ABC and SLC polymorphic variants and the outcome ... ...

Abstract	The efficacy of imatinib-based therapy depends on the proteins involved in its metabolism and transportation. Therefore, the aim of our study was to investigate the possible correlation of selected P450, ABC and SLC polymorphic variants and the outcome of imatinib therapy. A total of 101 patients with advanced, KIT/PDGFRA(+) GIST treated with imatinib were enrolled to the study. DNA was extracted from peripheral blood samples and genotypes were determined by PCR-RFLP and direct sequencing. Deviation from the Hardy-Weinberg equilibrium was only observed for rs2740574. None of the studied SNPs was associated with GIST time to progression. No significant correlation between any specific variant and time to progression was found in the group with KIT exon 11 mutation. However, individuals of at least three potentially unfavourable genotypes presented significantly shorter time to progression in comparison to patients with two or less unfavourable genotypes.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Cytochrome P-450 Enzyme System/genetics ; Drug Resistance, Neoplasm/genetics ; Exons/genetics ; Female ; Gastrointestinal Stromal Tumors/drug therapy ; Gastrointestinal Stromal Tumors/genetics ; Genotype ; Humans ; Male ; Middle Aged ; Mutation/genetics ; Polymerase Chain Reaction ; Polymorphism, Restriction Fragment Length/genetics ; Polymorphism, Single Nucleotide/genetics ; Solute Carrier Proteins/genetics
Chemical Substances	Antineoplastic Agents ; Solute Carrier Proteins ; Cytochrome P-450 Enzyme System (9035-51-2)
Language	English
Publishing date	2016-12-24
Publishing country	Czech Republic
Document type	Journal Article
ZDB-ID	419223-0
ISSN	0015-5500
ISSN	0015-5500
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 632: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Crossing Anatomic Barriers-Transplantation of a Kidney with 5 Arteries, Duplication of the Pyelocalyceal System, and Double Ureter.

Bachul, Piotr J / Osuch, Czesław / Chang, Ea-Sle / Bętkowska-Prokop, Alina / Pasternak, Artur / Szura, Mirosław / Matyja, Andrzej / Walocha, Jerzy A

Cell transplantation

2017 Volume 26, Issue 10, Page(s) 1669–1672

Abstract: During the time of organ harvest, it is crucial for the kidney procurement team to consider significant vascular anatomical variations. Multiple renal arteries are not uncommon, and unintentional injury can result in an irreversibly damaged kidney graft ... ...

Abstract	During the time of organ harvest, it is crucial for the kidney procurement team to consider significant vascular anatomical variations. Multiple renal arteries are not uncommon, and unintentional injury can result in an irreversibly damaged kidney graft that needs to be discarded. We present a kidney graft with 5 renal arteries and a single vein that was successfully procured and implanted with good graft function at discharge and at 4-yr follow-up. According to the literature, additional renal arteries can be found in about 33% of kidneys. This is the first study on a kidney with 5 arteries in the published literature, especially in the context of transplantation.
MeSH term(s)	Female ; Humans ; Kidney Pelvis/abnormalities ; Kidney Transplantation/methods ; Male ; Retrospective Studies ; Ureter/abnormalities
Language	English
Publishing date	2017-09-21
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1135816-6
ISSN	1555-3892 ; 0963-6897
ISSN (online)	1555-3892
ISSN	0963-6897
DOI	10.1177/0963689717722169
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3556: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure.

Sobczuk, Paweł / Teterycz, Paweł / Lugowska, Iwona / Klimczak, Anna / Bylina, Elżbieta / Czarnecka, Anna M / Kosela-Paterczyk, Hanna / Osuch, Czesław / Streb, Joanna / Rutkowski, Piotr

Oncology letters

2019 Volume 18, Issue 3, Page(s) 3373–3380

Abstract: The neutrophil-to lymphocyte ratio (NLR) has been proven to be correlated with outcomes in various cancer types, including gastrointestinal stromal tumors (GIST). There is limited data regarding the clinical value of NLR during second line therapy after ... ...

Abstract	The neutrophil-to lymphocyte ratio (NLR) has been proven to be correlated with outcomes in various cancer types, including gastrointestinal stromal tumors (GIST). There is limited data regarding the clinical value of NLR during second line therapy after failure of imatinib and there is an urgent need for more precise predictive factors for therapy. The aim of this study was to assess the association of the pretreatment NLR with progression free survival (PFS) and overall survival (OS) in patients with unresectable/metastatic GIST treated with sunitinib in a second line of treatment. In this analysis 146 out of 230 patients with unresectable/metastatic GIST were included, who were treated between 2005 and 2016 with sunitinib after failure of imatinib, with complete clinical data. In all patients, the NLR was assessed at baseline. The NLR cutoff of 2.4 was selected. The Kaplan-Meier method with the long-rank test and Cox proportional hazards model were applied for statistical analysis. Median PFS was 12.4 months with a 2-year rate of 27.1% and a 5-year rate of 4.8%. Median OS was 22.8 months, whereas 2- and 5-year rates were 47.8 and 13.8%, respectively. Patients with NLR>2.4 had significantly shorter OS: Median OS was 30 months for NLR≤2.4 vs. 16.4 months for NLR>2.4 (P=0.002); median PFS was 18.2 vs. 9.6 (P=0.075), respectively. In a multivariate model adjusted for mitotic index, primary location of tumor and driver mutation in
Language	English
Publishing date	2019-07-16
Publishing country	Greece
Document type	Journal Article
ZDB-ID	2573196-8
ISSN	1792-1082 ; 1792-1074
ISSN (online)	1792-1082
ISSN	1792-1074
DOI	10.3892/ol.2019.10622
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.

Osuch, Czesław / Rutkowski, Piotr / Brzuszkiewicz, Karolina / Bylina, Elżbieta / Limon, Janusz / Siedlecki, Janusz A

Polski przeglad chirurgiczny

2014 Volume 86, Issue 7, Page(s) 325–332

Abstract: Unlabelled: GIST is the most common mesenchymal tumour of gastrointestinal tract arising from mutation of KIT or PDGFRA gene. Surgery is the primary method of treatment, however a targeted therapy with imatinib is necessary due to recurrence. The aim of ...

Abstract	Unlabelled: GIST is the most common mesenchymal tumour of gastrointestinal tract arising from mutation of KIT or PDGFRA gene. Surgery is the primary method of treatment, however a targeted therapy with imatinib is necessary due to recurrence. The aim of the study was to evaluate efficacy of the targeted chemotherapy in advanced gastrointestinal stromal tumours with non-exon 11 KIT mutations. Material and methods: Data from 279 patients with advanced GIST treated with imatinib between 2001 and 2011 were analysed in the study. Exon 11 KIT mutation was found in 192 patients (68.7%), non-exon 11 KIT mutation was found in 87 patients (31.3%): this group included lack of mutation - wild-type, exon 9 KIT mutations, exon 18 PDGFRA D842V mutations, non-D842V PDGFRA mutations as well as non-exon 9 and 11 KIT mutations. Analysis of progression-free survival and overall survival were done for the entire group of patients and for patients with particular mutations, and then effects on progression-free survival and overall survival of such factors as sex, age, imatinib dose were evaluated. Results: Occurrence of non-exon 11 KIT mutation increases the risk of disease progression by 20% in comparison to the presence of exon 11 KIT mutation, however it does not increase the risk of patient's death. Percentage of 5-year progression-free survivals is the greatest in the case of PDGFRA mutation other than D842V mutation. Percentage of 5-year survivals in case of the presence of D842V PDGFRA mutation is more than twice worse than in the case of the other mutations. Lesion location in the gastrointestinal tract affected the risk of death, with the greatest percentage of 5-year survival for lesions located in the stomach. Such factors as sex, age at diagnosis (<50, ≥50 years) and imatinib dose did not affect the risk of disease progression and the risk of patient's death. Conclusions: The ratio of overall survival of patients with advanced GIST with a mutation other than exon 11 KIT mutation treated with imatinib is similar to the ratio of overall survival of patients with GIST with exon 11 KIT mutation. An exception is the group of patients with GIST in whom the presence of D842V PDGFRA mutation was found. In general, longer survival has been found in patients with GIST located in the stomach in comparison to the small intestine or other less frequent locations. Percentage of 5-year progression-free survivals is the greatest in the case of PDGFRA mutation other than D842V mutation.
MeSH term(s)	Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; DNA Mutational Analysis ; Disease Progression ; Disease-Free Survival ; Exons ; Female ; Gastrointestinal Stromal Tumors/drug therapy ; Gastrointestinal Stromal Tumors/genetics ; Genotype ; Humans ; Imatinib Mesylate/therapeutic use ; Male ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Sex Factors
Chemical Substances	Antineoplastic Agents ; Imatinib Mesylate (8A1O1M485B)
Language	English
Publishing date	2014-07
Publishing country	Poland
Document type	Comparative Study ; Journal Article
ZDB-ID	128732-1
ISSN	2299-2847 ; 0032-373X
ISSN (online)	2299-2847
ISSN	0032-373X
DOI	10.2478/pjs-2014-0057
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 375: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.

Rutkowski, Piotr / Ziętek, Marcin / Cybulska-Stopa, Bożena / Streb, Joanna / Głuszek, Stanisław / Jankowski, Michał / Łopacka-Szatan, Karolina / Las-Jankowska, Manuela / Hudziec, Piotr / Klimczak, Anna / Olesiński, Tomasz / Świtaj, Tomasz / Koseła-Paterczyk, Hanna / Bylina, Elżbieta / Osuch, Czesław

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

2020 Volume 47, Issue 5, Page(s) 1191–1195

Abstract: Introduction: The real-world data on adjuvant imatinib therapy in high-risk primary GIST are scarce.: Methods: We have analysed the data of 107 consecutive patients with gastrointestinal stromal tumour (GIST) after resection treated with adjuvant ... ...

Abstract	Introduction: The real-world data on adjuvant imatinib therapy in high-risk primary GIST are scarce. Methods: We have analysed the data of 107 consecutive patients with gastrointestinal stromal tumour (GIST) after resection treated with adjuvant imatinib (for planned 3 years with initial dose 400 mg daily, started not later than 4 months after operation) in 6 oncological centres in 2013-2018. All patients were required to have high risk of recurrence (at least 50% according to NCCN/AFIP criteria), known mutational status to exclude PDGFRA D842V mutants and KIT/PDGFRA-wild type cases from therapy without any further selection. Median follow-up time was 27 months. Results: The most common primary localization of GIST was small bowel (63 patients; 59%), followed by the stomach (40 patients; 37%). The majority of GIST cases harboured exon 11 KIT mutations (88 cases, 82%), 11 cases had exon 9 KIT mutations (10%), 8 had other KIT/PDGFRA mutations potentially sensitive to imatinib. Forty patients (37%) finished 3-year adjuvant imatinib therapy as planned, 48 (45%) still continue therapy, 5 (4.5%) patients had finished adjuvant therapy prematurely due to toxicity, 6 (6%) due to disease progression on treatment and 8 (7.5%) due to other reasons. The disease relapse was detected in 19 patients, of them in 5 cases in exon 9 KIT mutants (45%), and 14 cases in patients with exon 11 KIT mutations (11%) [p < 0.01]. Estimated 4-year relapse-free survival (RFS) rate is 78%. Conclusions: The early results of adjuvant therapy with imatinib in routine practice outside clinical trials in high-risk mutation-driven GIST patients only confirm high efficacy of this therapy with better tolerability than in clinical trials. We found overrepresentation of exon 9 KIT mutants and ruptured tumors in a group of patients with disease relapse.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Chemotherapy, Adjuvant ; Exons ; Female ; Follow-Up Studies ; Gastrointestinal Stromal Tumors/drug therapy ; Gastrointestinal Stromal Tumors/genetics ; Gastrointestinal Stromal Tumors/pathology ; Humans ; Imatinib Mesylate/therapeutic use ; Male ; Middle Aged ; Proto-Oncogene Proteins c-kit/genetics
Chemical Substances	Antineoplastic Agents ; Imatinib Mesylate (8A1O1M485B) ; Proto-Oncogene Proteins c-kit (EC 2.7.10.1)
Language	English
Publishing date	2020-08-16
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Observational Study
ZDB-ID	632519-1
ISSN	1532-2157 ; 0748-7983
ISSN (online)	1532-2157
ISSN	0748-7983
DOI	10.1016/j.ejso.2020.08.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1149: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 549: Show issues

Order via subito

Details ▾

Article: BRAF mutations in sporadic colorectal carcinoma from polish patients.

Wójcik, Piotr / Okoń, Krzysztof / Osuch, Czesław / Klimkowska, Agnieszka / Tomaszewska, Romana

Polish journal of pathology : official journal of the Polish Society of Pathologists

2010 Volume 61, Issue 1, Page(s) 23–26

Abstract: BRAF mutations are second to KRAS mutations in activation of the MAPK pathway in colorectal carcinoma cells. In addition to mutated KRAS, BRAF V600E mutation is associated with resistance to EGFR-targeted therapy in colorectal cancer; thus mutated BRAF ... ...

Abstract	BRAF mutations are second to KRAS mutations in activation of the MAPK pathway in colorectal carcinoma cells. In addition to mutated KRAS, BRAF V600E mutation is associated with resistance to EGFR-targeted therapy in colorectal cancer; thus mutated BRAF might serve as a predictive factor. In this study, 163 routinely resected adenocarcinomas were screened for mutations in exons 11 and 15 of the BRAF gene. Only 6 (3.7%) tumours had a missense point mutation (G469A, D594G, G596R, K601N and twice V600E). The tumours were locally advanced with multiple metastases to lymph nodes. Mutations were associated with microsatellite instability (2 cases MSI-H, 2 cases MSI-L) and mutually exclusive with a mutated KRAS gene. In this sample set, mutations in the BRAF gene were more diverse and less frequent than usually reported.
MeSH term(s)	Adenocarcinoma ; Colorectal Neoplasms ; Humans ; Microsatellite Instability ; Mutation ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins B-raf/genetics
Chemical Substances	Proto-Oncogene Proteins ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
Language	English
Publishing date	2010
Publishing country	Poland
Document type	Journal Article
ZDB-ID	1283064-1
ISSN	1233-9687 ; 0031-3114
ISSN	1233-9687 ; 0031-3114
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 377: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito